Table 1 Selected patient and tumor characteristics (at trastuzumab initiation) according to HER2 status
HER2 status | ||
|---|---|---|
Positive | Negative | |
N | 137 | 88 |
Age (years)1 | ||
Median (range) | 54.6 (28.4-95.0) | 58.9 (31.8-78.8) |
N (%) | N (%) | |
Menopausal status | ||
Premenopausal | 43 (31.4) | 26 (29.5) |
Postmenopausal | 94 (68.6) | 62 (70.5) |
Performance status | ||
0 | 96 (70.1) | 56 (63.6) |
1 | 28 (20.4) | 18 (20.5) |
2 | 5 (3.6) | 7 (8.0) |
Unknown | 8 (5.8) | 7 (7.8) |
History of adjuvant CT | 75 (54.7) | 55 (62.5) |
Anthracycline containing | 59 (43.1) | 29 (33.0) |
Taxane containing | 36 (26.3) | 17 (19.3) |
CMF-like | 42 (30.7) | 30 (34.1) |
History of adjuvant HT | 61 (44.5) | 42 (47.7) |
History of adjuvant RT | 52 (38.0) | 33 (37.5) |
Tumor grade (initial diagnosis) | ||
1 | 4 (2.9) | 2 (2.3) |
2 | 48 (35.0) | 36 (40.9) |
3 | 75 (54.7) | 42 (47.7) |
Unknown | 10 (7.3) | 8 (9.1) |
Site of metastases | ||
Locoregional | 45 (32.8) | 28 (31.8) |
Distant | 117 (85.4) | 78 (88.6) |
Only locoregional | 10 (7.3) | 5 (5.7) |
Only distant | 82 (59.9) | 55 (62.5) |
Bones | 54 (39.4) | 37 (42.0) |
Visceral | 93 (67.9) | 58 (65.9) |
Number of metastatic sites | ||
1 | 54 (39.4) | 28 (31.8) |
2 | 40 (29.2) | 30 (34.1) |
≥3 | 38 (27.7) | 25 (28.4) |
Unknown | 5 (3.6) | 5 (5.7) |
History of 1st line CT | 123 (89.8) | 68 (77.3) |
Anthracycline containing | 18 (13.1) | 9 (10.2) |
Number of treatment lines with T | ||
1 | 51 (37.2) | 39 (44.3) |
2 | 33 (24.1) | 19 (21.6) |
3 | 23 (16.8) | 12 (13.6) |
≥4 | 30 (21.9) | 18 (20.5) |